The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint-driven clinical trials in patients with chronic kidney disease and type 2 diabetes mellitus (FIDELIO-DKD and FIGARO...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311906/ https://www.ncbi.nlm.nih.gov/pubmed/37386461 http://dx.doi.org/10.1186/s12933-023-01899-0 |